Acorda Therapeutics Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Acorda Therapeutics Inc.

ACOR 0.880

-13.8%

Apr 10 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kenhott who wrote (10)	4/25/2008 12:40:37 PM
From: Arthur Radley	of 120

Acorda Therapeutic (ACOR) June & July volatility at 185 into data 8:36 AM EDT April 25, 2008 Acorda Therapeutic (Nasdaq: ACOR) : ACOR, a commercial stage biopharmaceutical company developing treatments to improve neurological functions, closed at $21.96. ACOR Fampridine-SR (MS treatment) Phase 3 data is expected soon. ACOR is expected to report Q1 EPS on May 5. ACOR May option implied volatility is at 99, June & July is at 158, above its 6-month average of 94 according to Track Data, suggesting larger uncertainty. Paul Foster

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next